DelveInsight’s, “Acute Myeloid Leukemia Pipeline Insight” report provides comprehensive insights about 110+ companies and 120+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemiaclinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acute Myeloid Leukemia Treatment Landscape. Click here to read more @ Acute Myeloid Leukemia Pipeline Outlook
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
- In January 2025:- Janssen Pharmaceuticals:- The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of bleximenib in phase 1 (Part 1 [Dose Escalation] and to determine the safety and tolerability at RP2D in Phase 1 Part 2 (Dose expansion). The purpose of the Phase 2 part of the study is to evaluate the efficacy of bleximenib at the RP2D.
- In January 2025:- Stemline Therapeutics Inc.:- This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day [μg/kg/day]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy.
- In January 2025:- Novartis Pharmaceuticals:- The primary purpose of this study was to test the hypothesis that preemptive treatment with sabatolimab, alone or in combination with azacitidine, when administered to participants with AML/secondary AML who were in complete remission with positive measurable residual disease post-allogeneic hematopoietic stem cell transplantation (MRD+ post-aHSCT), could enhance the graft versus leukemia (GvL) response and prevent or delay hematologic relapse without an unacceptable level of treatment-emergent toxicities, including clinically significant acute and/or chronic graft-versus-host disease (GvHD) and immune-related adverse events.
- DelveInsight’s Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 110+ active players working to develop 120+ pipeline treatment therapies.
- The leading Acute Myeloid Leukemia Companies such as GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
- Promising Acute Myeloid Leukemia Therapies such as OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
Discover groundbreaking developments in Acute Myeloid Leukemia therapies! Gain in-depth knowledge of key Acute Myeloid Leukemia clinical trials, emerging drugs, and market opportunities @ Acute Myeloid Leukemia Clinical Trials Assessment
Acute Myeloid Leukaemia Emerging Drugs Profile
- Uproleselan: GlycoMimetics
GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. Uproleselan is designed to bind to E-selectin and block the normal processes controlled by E-selectin. E-selectin is expressed on the surface of blood vessels, and its binding to myeloid cells confers a pro-survival effect via NF-kB signaling. Uproleselan is designed to provide a novel approach to disrupting established mechanisms of leukemic cell resistance. It is believed that by binding to E-selectin, uproleselan pushes AML cells out of their protective niche, blocks cellular communication signals that promote survival, and sensitizes cancer cells to the toxic effects of chemotherapy. Currently, the drug is in Phase III stage of its development for the treatment of Acute Myeloid Leukemia (AML).
- BST-236: BioSight
Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. Currently, the drug is in Phase II stage of its development for the treatment of Acute Myeloid Leukemia (AML).
- MK-0482: Merck Sharp & Dohme LLC
MK-0482, a novel humanized IgG4 mAb targeting ILT3, is undergoing phase I evaluation ±pembrolizumab (pembro) in advanced solid tumors. MK-0482 ± pembro was generally well tolerated, and combination therapy provided modest antitumor activity in patients with heavily pretreated advanced solid tumors. The RP2D of MK-0482 + pembro is under further evaluation in tumor-specific cohorts. Currently, the drug is in Phase I stage of its development for the treatment of AML.
- Ziftomenib – Kura Oncology
Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of AML. Currently, the drug is in Phase I/II stage of its development for the treatment of AML.
- SENTI 202: Senti Biosciences
SENTI-202 is a first in class Logic-gated CAR-NK product engineered with an OR and a NOT Logic Gate gene circuit approach to enhance therapeutic efficacy and safety, with additional arming via expression of calibrated release IL-15 (crIL-15). A dual targeting activating CAR (aCAR) that recognizes both CD33 and FLT3 tumor antigens improves the anti-tumor activity, ensuring the targeting of AML blasts and LSCs. Currently, the drug is in Preclinical stage of its development for the treatment of AML.
Stay informed about the Acute Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acute Myeloid Leukemia Unmet Needs
Acute Myeloid Leukemia Companies
GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
The Acute Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Acute Myeloid Leukaemia Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Transform your understanding of the Acute Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives
Scope of the Acute Myeloid Leukemia Pipeline Report
- Coverage- Global
- Acute Myeloid Leukemia Companies- GlycoMimetics, BioSight, Merck Sharp & Dohme LLC, Kura Oncology, Senti Biosciences, Chimerix, Takeda, Apollo Therapeutics, Immune-Onc Therapeutics, AbbVie/Genentech, Altor BioScience Corporation, Merck & Co, Astex Pharmaceuticals, Karyopharm Therapeutics, Mesoblast, SELLAS Life Sciences Group, Molecular Partners, Kling Biotherapeutics, HitGen, Chordia Therapeutics, Inc, Cullinan Therapeutics Inc., Aptose Biosciences Inc., Celgene and others.
- Acute Myeloid Leukemia Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
- Acute Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Acute Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Acute Myeloid Leukemia Pipeline Analysis Today! @ Acute Myeloid Leukemia Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Acute myeloid leukaemia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acute myeloid leukaemia – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Uproleselan: GlycoMimetics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- BST-236: BioSight
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- MK-0482: Merck Sharp & Dohme LLC
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- SENTI 202: Senti Biosciences
- Drug profiles in the detailed report…..
- Inactive Products
- Acute myeloid leukaemia Key Companies
- Acute myeloid leukaemia Key Products
- Acute myeloid leukaemia- Unmet Needs
- Acute myeloid leukaemia- Market Drivers and Barriers
- Acute myeloid leukaemia- Future Perspectives and Conclusion
- Acute myeloid leukaemia Analyst Views
- Acute myeloid leukaemia Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/testicular-cancer-pipeline-insight